RefleXion Medical, a therapeutic oncology company, raised $100m in a PSP Investments-led Series D funding round. RefleXion's existing investors, TPG's The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures and Johnson & Johnson Innovation all participated in the round. "This new influx of capital continues our momentum initiated first by FDA clearance of the RefleXion™ X1 platform last month, then quickly followed by the close of our first system order at one of the world's leading cancer centers. The support of this top-tier investment syndicate enables us to further scale operations around commercializing the X1 platform," Todd Powell, RefleXion President and CEO.